Behavioral and Immunohistochemical Evidence for Suppressive Effects of Goshajinkigan on Salicylate-Induced Tinnitus in Rats

Koichi Kitano 1,2, Akinori Yamashita 3, Taketoshi Sugimura 2, Tadao Okayasu 1, Masaharu Sakagami 1, Daisuke Osaki 1, Tadashi Kitahara 1,* and Yasuhiko Saito 2, *

1 Department of Otolaryngology–Head and Neck Surgery, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan; k-kitano@naramed-u.ac.jp (K.K.); akinori@naramed-u.ac.jp (A.Y.); tokayasu@naramed-u.ac.jp (T.O.); m.sakagami@naramed-u.ac.jp (M.S.); dosaki@naramed-u.ac.jp (D.O.)
2 Department of Neurophysiology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan; sugimura@naramed-u.ac.jp
* Correspondence: tkitahara@naramed-u.ac.jp (T.K.); syasu@naramed-u.ac.jp (Y.S.); Tel.: +81-744-22-3051 (T.K.); +81-744-29-8827 (Y.S.)

Abstract: Many people are affected by tinnitus, a sensation of ringing in the ear despite the absence of external sound. Goshajinkigan (GJG) is one of the formulations of Japanese traditional herbal medicine and is prescribed for the palliative treatment of patients with tinnitus. Although GJG is clinically effective in these patients, its behavioral effects and the underlying neuroanatomical substrate have not been modeled in animals. We modeled tinnitus using salicylate-treated rats, demonstrated the effectiveness of GJG on tinnitus, and examined the underlying neuronal substrate with c-Fos expression. Intraperitoneal injection of sodium salicylate (400 mg/kg) into rats for three consecutive days significantly increased false positive scores, which were used to assess tinnitus behavior. When GJG was orally administered one hour after each salicylate injection, the increase in tinnitus behavior was suppressed. The analysis of c-Fos expression in auditory-related brain areas revealed that GJG significantly reduced the salicylate-induced increase in the number of c-Fos-expressing cells in the auditory cortices, inferior colliculus, and dorsal cochlear nucleus. These results suggest a suppressive effect of GJG on salicylate-induced tinnitus in animal models.

Keywords: tinnitus; salicylate; animal model; Kampo; goshajinkigan; c-Fos; rat

1. Introduction

Many people are affected nowadays by tinnitus, a ringing sensation in the ear despite the absence of external sound. The prevalence of symptomatic tinnitus in the general population is in the range of 3.0–30.9% [1]. A population-based cohort study reported that in Japan, 11.9% of adult people experienced tinnitus [2]. Because symptoms of tinnitus are mostly subjective, its objective examination and effective evaluation of therapeutic strategies have been difficult to establish. For an objective evaluation of tinnitus, the study of its mechanisms, and development of preventive/therapeutical interventions, animal models of tinnitus can be useful. So far, tinnitus has been induced in animals by exposure to intense noise or administration of ototoxic drugs such as salicylate and quinine [3–5]. Tinnitus induction has been assessed using various behavioral tests, namely unconditioned gap detection startle reflex procedure [6], conditioned lick suppression [7,8], conditioned lever response suppression [9,10], and conditioned pole jumping avoidance [11].

Goshajinkigan (GJG; TJ-107, Tsumura & Co., Tokyo, Japan) is one of the popular Japanese traditional herbal medicines, the so-called Kampo medicines. GJG is composed of 10 herbal medicines in fixed proportions: Rehmanniae radix 5.0 g, Achyranthis radix 3.0 g, Corni fructus 3.0 g, Moutan cortex 3.0 g, Alismatis rhizome 3.0 g, Dioscoreae rhizome 3.0 g, Plantaginis semen 3.0 g, Hoelen 3.0 g, processed Aconiti tuber 1.0 g, and Cinnamomi...
cortex 1.0 g. GJG is usually prescribed for lower back pain, numbness in the extremities, dysuria, and diabetic neuropathy [12–14]. Traditionally, GJG has been palliatively used to treat patients for tinnitus. Ohnishi et al. [15] reported that in a multicenter clinical trial, GJG improved tinnitus symptoms in 66.7% of patients. Although GJG appears to be clinically effective for patients with tinnitus, no sufficient evidence exists in animal models. If GJG were applicable to animal models, the GJG effects on tinnitus could be objectively assessed, and its suppression of tinnitus may provide clues for the mechanisms responsible for tinnitus development and progression.

In the present study, we examined the effects of GJG on tinnitus in an animal model: footshock avoidance behavior conditioned by auditory stimuli [16] in salicylate-treated rats. Previous studies have shown that salicylate treatment increases the expression of c-Fos protein in several brain areas, including those related to auditory processing [17–21]. Therefore, we examined changes in c-Fos expression in auditory-related brain areas following oral GJG administration to rats that had received salicylate.

2. Materials and Methods

2.1. Animals

Experimental procedures involving animals were in accordance with the National Institutes of Health (NIH) guidelines for the Care and Use of Laboratory Animals and were approved by the Animal Care and Use Committee at Nara Medical University. All efforts were made to minimize the suffering of animals and to limit the number of animals used. A total of 150 male Wistar rats (8–23 postnatal weeks; Japan SLC, Hamamatsu, Japan) with body weights of 170–360 g was used in this study. Rats were individually housed in a temperature-controlled room at a constant 12 h light/dark cycle (lights off at 8:00 PM) and had free access to food and tap water. All behavioral tests were conducted during the animals' activity period (dark phase) at approximately the same time of the day.

2.2. Behavioral Assessment of Tinnitus

To assess tinnitus in rats, we used the behavioral model of salicylate-induced tinnitus described by Kizawa et al. [16], which was a modified version of the protocol reported by Guitton et al. [11]. Rats were trained to respond to a conditioned stimulus. Conditioning and behavioral testing were performed using a shuttle box (L: 20 cm, W: 48 cm, H: 20 cm) in a soundproof room. The box consisted of two chambers separated by a 3-cm high wall. Each chamber had an electrified floor where electrical shocks could be applied independently. The paradigm was so escapable that rats easily moved to the next chamber.

A 5 s pure tone sound with a frequency of 12, 16, or 20 kHz was used as the conditioned stimulus, and a 3.7-mA electrical footshock for a maximum of 30 s was given as the unconditioned stimulus. The footshock started 1 s after the end of the 5 s sound stimulus and was applied to the room the rat stayed in when the sound stimulus was presented. The footshock was stopped when the rat moved to the opposite room to escape the footshock. One trial consisted of a sound presentation followed by a footshock. The intertrial interval (silent period) was at least 1 min. A session of 10 trials lasted 15–20 min (Figure 1A). The ratio of correct avoidance movements in response to sound stimuli within 6 s (5 s during the sound presentation plus 1 s before the electrical footshock) was designated as the active avoidance (AA) score. The number of movements to the opposite side without sound stimulation during the intertrial interval was defined as the false positive (FP) score. The more the rats experienced tinnitus, the more the FP scores increased. A lower AA score indicated the occurrence of hearing loss [16]. When AA scores reached 80% or more in three consecutive sessions, the conditioning was complete, and rats underwent behavioral tests.

The behavioral test, composed of 10 trials for 15 min, was performed once daily for 4 days, at the same time of the day (Figure 1B). Animals received daily intraperitoneal (i.p.) injections of 1 mL saline containing 400 mg/kg sodium salicylate (SS; FUJIFILM Wako Pure Chemical Industries, Ltd., Osaka, Japan) on days 1–3. Behavioral measurements were performed 2 h after injections. To check the reversibility of salicylate effects [9,16], rats
underwent an additional test without salicylate injection on day 4. The AA and FP scores were determined throughout the behavioral test. When the AA scores were above 80% or more throughout the 4 days, the FP scores on day 3 were adopted as data.

**Figure 1.** Schematic representation of the behavioral test protocol. (A) Conditioning protocol. Animals were conditioned to move to the opposite chamber in response to a sound presentation. Each session of 10 trials lasted 15–20 min. When conditioned (criterion: three consecutive sessions with an active avoidance (AA) score ≥ 80%), animals underwent the behavioral tests. (B) Behavioral tests. In the salicylate administration protocol (B1), salicylate was intraperitoneally injected 2 h before the behavioral measurement (i.p., pink arrow). In this behavioral test, the correct movements to sound (AA score) and the movements during intertrial periods without sound (false positive (FP) score) were measured in a 15 min session. The drug was intraperitoneally injected daily for three days, and the behavioral test was performed daily for four days. In the goshajinkigan (GJG) administration protocol (B2), salicylate was intraperitoneally injected 2 h before the behavioral measurement (i.p., light brown arrow). Distilled water or GJG was orally administered (p.o., dark brown arrow) 1 h before the behavioral measurement. For the control group, animals received daily i.p. saline injections and following oral administration of DW. The i.p. and p.o. administrations were performed daily for three days, and the behavioral test was performed daily for four days.

We conditioned 96 rats for verification of the behavioral tests. According to Kizawa et al. [16], FP scores in salicylate-treated rats are dependent on sound intensity and frequency, and the most appropriate conditioning is at 60 dB sound pressure level (SPL) and 16 kHz. To verify the sound intensity and frequency in our experiments, we conducted the behavioral tests using the sound stimuli at intensities of 40 (n = 19), 60 (n = 31) and 80 (n = 12) dB SPL (16 kHz), and at frequencies of 12 (n = 17), 16 (previously shown), and 20 (n = 17) kHz (60 dB SPL) (Figure 1(B1)).

Moreover, we examined the behavioral tests following GJG administration. For the control group (n = 9), rats received daily i.p. saline injections following oral administration of DW. Salicylate-treated rats were divided into three groups: SS + DW group (n = 9), SS + GJG (0.3) group (n = 9), and SS + GJG (1.0) group (n = 9). In addition to i.p. salicylate injections, rats received daily oral administration of distilled water (DW, 10 mL/kg) with or without GJG (0.3 or 1.0 g/kg) on days 1–3 (Figure 1(B2)). The GJG dose was determined according to the results of previous studies [22–24]. GJG was administered 1 h after the injection of salicylate. One hour after GJG administration, the behavioral test was started.
The intensity and frequency of the sound stimuli were set at 60 dB SPL and 16 kHz, respectively, as described previously [16].

2.3. Immunohistochemical Analysis of c-Fos Expression in the Auditory Pathway

Separate from the behavioral tests, 18 rats were divided into three groups for the immunohistochemical analysis: (1) Saline + DW group, (2) SS + DW group, and (3) SS + GJG (1.0 g/kg) group (n = 6 in each group). Saline or GJG (1.0 g/kg) was orally administered to rats 1 h after the injection of salicylate on days 1–3 of Figure 1(B2). One hour after DW or GJG administration on day 3, rats were anesthetized with isoflurane inhalation and a mixture of medetomidine (0.15 mg/kg), midazolam (2.0 mg/kg), and butorphanol (2.5 mg/kg) i.p. injection, and transcardially perfused with 0.01 M phosphate-buffered saline (PBS, pH 7.4), followed by 4% paraformaldehyde in 0.1 M phosphate buffer. After 18–21 h fixation, the brains were cut into 50-µm coronal sections using a microslicer (Zero 1; Dosaka, Kyoto, Japan). Brain slices were obtained from the auditory-related brain regions, including the primary auditory cortex (A1), secondary auditory cortex dorsal and ventral zone (AuD and AuV), dorsal cochlear nucleus (DC), central nucleus of the inferior colliculus (ICc), and medial geniculate body (MGB). The approximate rostrocaudal locations of the brain regions from the bregma were determined as follows: from −5.15 mm to −4.85 mm in the A1, AuD, and AuV, from −11.04 mm to −10.89 mm in the DC, from −8.91 mm to −8.61 mm in the ICc, and from −5.15 mm to −4.85 mm in the MGB, according to the rat brain atlas [25]. Of the six slices that were usually obtained, three well-prepared slices proceeded to immunohistochemistry. In this study, we used c-Fos rabbit mAb (1:1000; Cell Signaling Technology, Danvers, MA, USA #2250) as the primary antibody and goat anti-rabbit IgG antibody (1:200; Thermo Fisher Scientific, Waltham, MA, USA A11008) as the secondary antibody. The slices were washed with 25 mM PBS, blocked in PBS containing 5% bovine serum albumin, 0.1% Triton X-100, and 0.1% NaN₃ for 1 h, and incubated with the primary antibody overnight at room temperature. Then, they were washed in PBS and incubated with the secondary antibody for 2 h. After washing in PBS, the slices were counterstained with Red fluorescent Nissl stain (1:200, Neurotrace 530/615; Thermo Fisher Scientific, Waltham, MA, USA) using antifade medium (ProLong Gold antifade reagent; Invitrogen, Carlsbad, CA, USA).

2.4. Observation and Data Analysis of Immunohistochemical Stainings

Brain sections were observed under a laser-scanning confocal microscope (C2+, Nikon). Confocal images observed with a 10× (for the AC and MGB) or 20× (for the DC and IC) objective were captured and stitched together using Nikon NIS Elements software. The numbers of c-Fos-positive nuclei were counted automatically using the “Analyze Particles” function of Fiji software [26]. In the auditory cortices, layer 4 showed a higher cell density than the surrounding layers 3 and 5, which was evident in the Nissl stainings. Therefore, layer 4 was used as a landmark, and layers 1–4 and 5–6 were determined as the superficial and deep layers, respectively.

2.5. Statistical Analysis

All values are shown as the median [interquartile range (IQR) 25–75]. The number (n) refers to the number of rats analyzed unless otherwise noted. Statistical analysis was performed using the Mann–Whitney U test or the Kruskal–Wallis test followed by Dunn’s test for multiple comparisons, and the adjusted p value was calculated. Differences in variance among groups were assessed using Bartlett’s test. The Wilcoxon test was used to compare data on day 3 and day 4 (Table 1). All analyses were performed using GraphPad Prism ver.9 (GraphPad Software, San Diego, CA). The threshold for statistical significance was defined as p < 0.05.
3. Results

3.1. Effect of Sound Intensity and Frequency on FP

At a stimulus of 16-kHz frequency, comparison of the FP scores on day 3 among groups exposed to different sound intensities revealed that the scores were higher at 40 dB and 60 dB than at 80 dB (*p = 0.049 in 40 dB vs. 80 dB, ***p = 0.0003 in 60 dB vs. 80 dB, Dunn’s test; Figure 2A). The FP scores at 60 dB were not significantly different from those at 40 dB (p = 0.385, Dunn’s test). The AA score was not significantly different among the three different intensities (p > 0.999 in 40 dB vs. 60 dB, p > 0.999 in 40 dB vs. 80 dB, p = 0.785 in 60 dB vs. 80 dB, Dunn’s test).

| Intensity (SPL) | Frequency (Hz) | FP on Day 3 Median (IQR) | FP on Day 4 Median (IQR) | p Value       |
|-----------------|----------------|-------------------------|-------------------------|---------------|
| 40 dB           | 16 k           | 4.0 (2.0–4.0)           | 1.0 (0.0–3.0)           | **p = 0.0013  |
| 60 dB           | 16 k           | 5.0 (2.0–9.0)           | 2.0 (1.0–4.0)           | ****p < 0.0001|
| 80 dB           | 16 k           | 1.0 (1.0–3.0)           | 0.0 (0.0–1.0)           | *p = 0.0313   |
| 60 dB           | 12 k           | 6.0 (3.5–8.0)           | 1.0 (0.5–5.0)           | **p = 0.0065  |
| 60 dB           | 20 k           | 3.0 (1.0–5.0)           | 1.0 (0.0–2.0)           | **p = 0.0076  |

Scores on days 3 and 4 are compared, and all show a significant decrease in the Wilcoxon test. Data are presented as median (interquartile range (IQR) 25–75). FP: false positive, SPL: sound pressure level, SS: sodium salicylate. Asterisks indicate a significant difference between groups (*p < 0.05; **p < 0.01; ****p < 0.0001).

3.1.1. Comparison of FP scores on days 3 and 4.

At a stimulus of 16-kHz frequency, comparison of the FP scores on day 3 among groups exposed to different sound frequencies revealed that the scores were not significantly different among the three frequencies (*p = 0.119 in 12 kHz vs. 16 kHz, p = 0.275 in 12 kHz vs. 20 kHz, p > 0.999 in 16 kHz vs. 20 kHz, Dunn’s test). On day 4, when salicylate was not administered to rats, the FP scores significantly decreased compared with the scores measured on the preceding day (Table 1), confirming a reversible salicylate effect in this behavioral test [9,16].

**Figure 2.** Verification of the sound intensity and frequency in salicylate-treated rats. (A) Comparison by intensity on day 3. At a stimulus of 60 dB SPL, comparison of the FP scores in three groups conditioned with sound pressures of 40 dB (n = 19), 60 dB (n = 31), and 80 dB (n = 12). The FP scores at 40 dB and 60 dB were significantly higher than those at 80 dB (*p = 0.049 in 40 dB vs. 80 dB, ***p = 0.0003 in 60 dB vs. 80 dB, Kruskal–Wallis test and Dunn’s test). (B) Comparison by frequency on day 3. At a stimulus of 60 dB SPL, comparison of the FP scores in three groups conditioned with sound frequencies of 12 kHz (n = 17), 16 kHz (n = 31), and 20 kHz (n = 17). No significant difference was observed among these three groups. Data are presented as median (interquartile range).
3.2. Effect of GJG on FP scores

Salicylate injection caused an increase in FP scores at 16 kHz and 60 dB, i.e., the number of movements to the opposite test chamber without a sound stimulus (**p = 0.0002, Mann–Whitney U test; Figure 3A).

When a high GJG dose (1.0) was administered to salicylate-treated rats, the FP scores on day 3 in the SS + DW group were significantly lower than those in the SS + GJG (1.0) group (*p = 0.021, Dunn’s test; Figure 3B). Administration of low-dose GJG (0.3) did not lead to significant differences in FP scores (p = 0.275 in SS + DW vs. SS + GJG (0.3), p = 0.948).

Figure 3. Effect of goshajinkigan (GJG) administration on false positive (FP) and active avoidance (AA) scores in salicylate-treated rats. (A) Comparison of FP scores between Saline + distilled water (DW) group and sodium salicylate (SS) + DW group (n = 9 in each group). The FP scores in the SS + DW group were significantly higher than those in the Saline + DW group (**p = 0.0002, Mann–Whitney U test). (B) Comparison of FP scores among three groups: SS + DW group, SS + GJG (0.3) group, and SS + GJG (1.0) group (n = 9 in each group). The FP scores in the SS + GJG (1.0) group were significantly lower than those in the SS + DW group (*p = 0.021, Kruskal–Wallis test and Dunn’s test). No significant difference was observed between the SS + DW and SS + GJG (0.3) (p = 0.275, Kruskal–Wallis test and Dunn’s test) or SS + GJG (0.3) and SS + GJG (1.0) groups (p = 0.948, Kruskal–Wallis test and Dunn’s test). (C) Comparison of AA scores between the Saline + DW group and SS + DW group. Both groups showed AA scores ≥ 80% without significant differences. (D) Comparison of AA scores in three groups: SS + DW group, SS + GJG (0.3) group, and SS + GJG (1.0) group. All groups showed AA scores ≥ 80% with no significant group differences. Data are presented as median (interquartile range). A learning curve was created to show the progression of AA scores until these groups completed conditioning (see Supplementary Figure S1).

When a high GJG dose (1.0) was administered to salicylate-treated rats, the FP scores on day 3 in the SS + GJG (1.0) group were significantly lower than those in the SS + DW group (**p = 0.021, Dunn’s test; Figure 3B). Administration of low-dose GJG (0.3) did not lead to significant differences in FP scores (p = 0.275 in SS + DW vs. SS + GJG (0.3), p = 0.948.
in SS + GJG (0.3) vs. SS + GJG (1.0), respectively, Dunn’s test). The AA scores were higher than 80% and not significantly different among these groups (Figure 3C,D and Figure S1).

3.3. Effect of GJG on c-Fos Expression

To clarify whether the behavioral change in salicylate-treated rats by GJG administration was attributable to changes in neuronal activity, we investigated the expression of c-Fos in several brain areas related to auditory functions (Figure 4A). After salicylate injection, the number of c-Fos-expressing cells was considerably increased in the primary (A1) and secondary (AuD and AuV) auditory cortices (Figure 4B). The numbers of c-Fos-expressing cells in salicylate-treated rats (SS + DW group) were significantly higher than those in control rats (Saline + DW group) in the A1 (****p < 0.0001, Mann–Whitney Utest), AuD (****p < 0.0001, Mann–Whitney Utest), and AuV (****p < 0.0001, Mann–Whitney Utest; Figure 4C, Table 2). Such salicylate-induced increases in the number of c-Fos-expressing cells were observed in both superficial and deep layers (Figure 4D).

Table 2. Effect of goshajinkigan (GJG) administration on c-Fos expression in the auditory cortex of salicylate-treated rats.

| Area         | Group         | c-Fos Expressing Cells | p Value         |
|--------------|---------------|------------------------|-----------------|
|              |               | Median (IQR)           |                 |
| A1 total     | Saline + DW   | 205 (143–286)          | ****p < 0.0001  |
|              | SS + DW       | 583 (442–641)          | ****p < 0.0001  |
|              | SS + GJG      | 264 (227–381)          | ****p < 0.0001  |
| AuD total    | Saline + DW   | 218 (134–343)          | ****p < 0.0001  |
|              | SS + DW       | 641 (382–837)          | **p = 0.004     |
|              | SS + GJG      | 297 (214–518)          |                 |
| AuV total    | Saline + DW   | 221 (157–308)          | ****p < 0.0001  |
|              | SS + DW       | 595 (484–760)          | 0.059           |
|              | SS + GJG      | 499 (382–567)          |                 |
| A1 superficial | Saline + DW    | 264 (187–339)          | ****p < 0.0001  |
|              | SS + DW       | 630 (436–825)          | ****p < 0.0001  |
|              | SS + GJG      | 290 (235–355)          | ****p < 0.0001  |
| AuD superficial | Saline + DW   | 255 (164–378)          | **p = 0.002     |
|              | SS + DW       | 632 (288–1013)         | *p = 0.021      |
|              | SS + GJG      | 328 (191–521)          |                 |
| AuV superficial | Saline + DW   | 290 (176–509)          | ***p = 0.0007   |
|              | SS + DW       | 624 (439–869)          | p = 0.214       |
|              | SS + GJG      | 561 (362–686)          |                 |
| A1 deep      | Saline + DW   | 149 (104–186)          | ****p < 0.0001  |
|              | SS + DW       | 445 (352–599)          | **p = 0.002     |
|              | SS + GJG      | 286 (192–401)          |                 |
| AuD deep     | Saline + DW   | 127 (92–221)           | ****p < 0.0001  |
|              | SS + DW       | 630 (431–764)          | ****p < 0.0001  |
|              | SS + GJG      | 301 (212–511)          | ****p < 0.0008  |
| AuV deep     | Saline + DW   | 171 (122–253)          | ****p < 0.0001  |
|              | SS + DW       | 531 (408–777)          | p = 0.069       |
|              | SS + GJG      | 434 (364–509)          |                 |

The number of c-Fos-expressing cells are compared. Mann–Whitney U test. A1: primary auditory cortex, AuD: secondary auditory cortex dorsal zone, AuV: secondary auditory cortex ventral zone, SS: sodium salicylate, DW: distilled water, IQR: interquartile range. Asterisks indicate a significant difference between groups (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
Figure 4. Effect of goshajinkigan (GJG) administration on c-Fos expression in the auditory cortex of salicylate-treated rats. (A) A low magnification fluorescent photomicrograph of the auditory cortex. The primary (A1) and dorsal (AuD) and ventral (AuV) secondary auditory cortexes were separated based on Nissl staining (shown in magenta). Layers 1–4 and 5–6 were defined as superficial and deep layers, respectively (yellow dotted lines). Scale bar = 500 μm. (B) Fluorescent photomicrographs in the areas of the A1, AuD, and AuV. Green dots show c-Fos-expressing cells in the Saline + distilled water (DW) group (left), sodium salicylate (SS) + DW group (center), and SS + GJG group (right). Scale bars = 100 μm. (C) Comparison of the numbers of c-Fos-expressing cells in the Saline + DW, SS + DW, and SS + GJG groups. In the A1 and AuD, cell numbers in the SS + DW group were significantly higher than those in the Saline + DW and SS + GJG groups. In the AuV, the number in the SS + DW group was significantly higher than the number in the Saline + DW group. (D) Comparison of the numbers of c-Fos-expressing cells in the superficial and deep layers. In both superficial and deep layers of the A1 and AuD, the numbers in the SS + DW group were significantly higher than those in the Saline + DW and SS + GJG groups. In the superficial and deep layers of the AuV, the numbers in the SS + DW group were significantly higher than those in the Saline + DW group. Data are presented as median (interquartile range) and are analyzed using the Mann–Whitney U test, n = 6 in each group. Asterisks indicate a significant difference between groups (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
When GJG was administered to salicylate-treated rats, the number of c-Fos-expressing cells was significantly reduced in the A1 (**** \( p < 0.0001 \), Mann–Whitney \( U \) test) and AuD (** \( p = 0.004 \), Mann–Whitney \( U \) test) but not in the AuV (\( p = 0.059 \) in SS + DW vs. SS + GJG, Mann–Whitney \( U \) test; Figure 4C). GJG-induced decreases in the numbers of c-Fos-expressing cells were observed in superficial and deep layers of the A1 and AuD (**** \( p < 0.0001 \) in A1 superficial, ** \( p = 0.0002 \) in A1 deep, * \( p = 0.021 \) in AuD superficial, *** \( p = 0.0008 \) in AuD deep, Mann–Whitney \( U \) test; Figure 4D).

In the auditory thalamus and brainstem, changes in the numbers of c-Fos-expressing cells were observed following salicylate and GJG administration (Figure 5, Table 3). In the MGB, salicylate injection significantly increased the number of c-Fos-expressing cells (*** \( p = 0.008 \), Mann–Whitney \( U \) test), but GJG administration did not lead to a significant decrease in their number (\( p = 0.097 \), Mann–Whitney \( U \) test). In the DC and IC, GJG treatment caused a significant decrease in the number of c-Fos-expressing cells (* \( p = 0.016 \) in the DC, ** \( p = 0.010 \) in the ICc, Mann–Whitney \( U \) test), although salicylate injection did not significantly increase their number (\( p = 0.406 \) in the DC, \( p = 0.126 \) in the IC, Mann–Whitney \( U \) test).

**Figure 5.** Effect of goshajinkigan (GJG) administration on c-Fos expression in the auditory thalamus and brainstem nuclei of salicylate-treated rats. (A) Fluorescent photomicrographs of the medial geniculate body (MGB), dorsal cochlear nucleus (DC), and central nucleus of the inferior colliculus (ICc). These areas were separated based on Nissl stainings (shown in magenta) in low magnification fluorescent photomicrographs (leftmost column). Green dots show c-Fos-expressing cells in the Saline + DW group (second column), sodium salicylate (SS) + DW group (third column), and SS + GJG group (rightmost column). Scale bars = 500 \( \mu \)m (leftmost column) and 100 \( \mu \)m (rightmost column). (B) Comparison of the numbers of c-Fos-expressing cells in Saline + DW, SS + DW, and SS + GJG groups. In the MGB, the number of c-Fos-expressing cells was significantly larger in the SS + DW group than in the Saline + DW group. In the DC and ICc, cell numbers in the SS + DW group were significantly higher than those in the SS + GJG group. Data are presented as median (interquartile range) and are analyzed using the Mann–Whitney \( U \) test, \( n = 6 \) in each group. Asterisks indicate a significant difference between groups (* \( p < 0.05 \); ** \( p < 0.01 \)).
Table 3. Effect of goshajinkigan (GJG) administration on c-Fos expression in the auditory thalamus and brainstem nuclei of salicylate-treated rats.

| Area | Group       | c-Fos Expressing Cells Median (IQR) | p Value |
|------|-------------|------------------------------------|---------|
|      |             |                                    |         |
| MGB  | Saline + DW | 4 (0–28)                           | **p = 0.008 |
|      | SS + DW     | 38 (12–72)                         | p = 0.097  |
|      | SS + GJG    | 13 (5–40)                          |         |
| DC   | Saline + DW | 167 (117–229)                      | p = 0.406  |
|      | SS + DW     | 206 (116–357)                      | *p = 0.016 |
|      | SS + GJG    | 123 (62–168)                       |         |
| Icc  | Saline + DW | 161 (91–253)                       | p = 0.126  |
|      | SS + DW     | 229 (156–264)                      | **p = 0.010 |
|      | SS + GJG    | 138 (76–221)                       |         |

The number of c-Fos-expressing cells are compared. Mann–Whitney U test. MGB: medial geniculate body, DC: dorsal cochlear nucleus, Icc: central nucleus of inferior colliculus, SS: sodium salicylate, DW: distilled water, IQR: interquartile range. Asterisks indicate a significant difference between groups (*p < 0.05; **p < 0.01).

4. Discussion

In the present study, we investigated the effects of GJG, which is clinically used for the palliative treatment of patients with tinnitus, and on behavioral and immunohistochemical parameters in salicylate-treated rats. GJG administration reduced the FP score and number of c-Fos-expressing neurons in rats. These results indicate that GJG is also effective for tinnitus treatment in animal models, and that this animal model is helpful in the study of its mechanisms and development of preventive/therapeutic interventions.

For the assessment of tinnitus induction, rats underwent the AA task using a protocol similar to that described in a previous study [16]. Comparing FP scores obtained from conditioning with different sound intensities and frequencies, Kizawa et al. [16] proposed that the conditioned stimulus of 60 dB and 16 kHz was the most appropriate for detecting tinnitus induction in rats that received 400 mg/kg salicylate for 3 days. Our present study showed no significant difference in FP scores at 40 dB and 60 dB although they were significantly higher than the scores at 80 dB. In addition, no significant differences in FP scores were found among 12-kHz, 16-kHz, and 20-kHz stimuli. These results suggest that the appropriate intensities and frequencies for the conditioned stimulus are somewhat broadly distributed. This finding supports those of previous reports, in which sound pressures of around 60 dB [27–30] and sound frequencies in the range of 10–16 kHz [9,11,30–33] were used for detection of tinnitus behaviors in salicylate-treated animals. An injection of salicylate significantly increased the FP score. However, the fact that high AA scores (≥ 80%) in salicylate-treated rats were comparable with those in control rats suggests that salicylate did not induce hearing loss in rats. Furthermore, a significant decrease in FP scores on the 4th day of the behavioral test session when salicylate was not applied to rats was demonstrated. This reversible effect of salicylate suggests that salicylate did not induce obvious functional damage to endocochlear organs. This reversible effect could be caused by a decreasing effect of cochlear blood flow [34].

This animal study was performed to objectively evaluate the effects of GJG on tinnitus. GJG was administered to rats at two different doses, 0.3 g/kg and 1.0 g/kg, which were higher than the daily dose clinically prescribed for patients (approximately 0.1 g/kg). However, these doses were also used in previous studies that evaluated the effects of GJG in a mouse model of streptozotocin-induced diabetes mellitus [23] and a rat model of oxaliplatin-induced acute peripheral neuropathy [22,24]. GJG administration at these doses caused a potent antinociceptive effect in the diabetic mice and prevented oxaliplatin-induced acute neuropathy, such as cold hyperalgesia and mechanical allodynia in the neuropathic rats. Therefore, we considered these doses appropriate for evaluating GJG effects in animal experiments. The salicylate-induced increase in FP score was significantly
suppressed by administration of 1.0 g/kg GJG. This result suggests that GJG is effective for the suppression of tinnitus behavior in salicylate-treated rats.

Our present immunohistochemical study showed that the application of salicylate significantly increased the number of c-Fos-expressing cells in the primary and secondary auditory cortices and the MGB. These results correspond to findings of a previous study in gerbils [18]. In addition, our finding that the number of c-Fos-expressing cells was higher in superficial layers than in deep layers is in agreement with a previous result where c-Fos labeling peaks in layers 3 and 4 [20]. An enhancement of neural activity after salicylate application was also electrophysiologically demonstrated in the auditory cortex of cats and rats [30,35–37]. In auditory brainstem regions such as the DC and ICc, a significant increase in the number of c-Fos-expressing cells was not observed in salicylate-treated rats. This agrees with the salicylate-induced tinnitus model reported by Lanaia et al. [38]. They adopted the behavioral assessment of tinnitus using somatic resonance, where the DC played an important role. Their results indicate that the DC is not involved in salicylate-induced tinnitus but is involved in trauma-induced tinnitus. Our results are also consistent with those of Wu et al. [19], who found no increase in c-Fos in the DC, but not with those of Santos et al. [21], who found increases in the DC and ICc. These inconsistent findings may be attributed to different experimental conditions, such as different doses and periods of salicylate treatment, and time from SS administration to fixation (250 mg/kg salicylate for 5 days fixation after 8 h [19] and 300 mg/kg salicylate for 3 days fixation after 3 h [21], respectively).

When GJG was administered to salicylate-treated rats, significant decreases in the numbers of c-Fos-expressing cells were observed in the A1, AuD, DC, and ICc. A previous study has reported that salicylate application enhances functional connectivity of the auditory networks composed of the IC, MGB, and auditory cortices, in addition to nonauditory structures, such as the amygdala and cerebellum [39,40]. Our immunohistochemical results strongly suggest that brain regions such as the A1, AuD, DC, and ICc participate in salicylate-induced tinnitus.

Salicylate-induced tinnitus can be caused by peripheral and central effects. Because salicylate affects outer hair cells and auditory nerves [11,41–43], salicylate may have affected the peripheral auditory system, resulting in interactions with the central auditory system. Because salicylate can penetrate the blood–brain barrier [44–46], it has been reported that salicylate directly affects the central auditory system [39,47,48]. In vitro studies using brain slices have revealed that the application of salicylate modulates inhibitory synaptic responses and electrophysiological properties of central neurons [49–54]. Salicylate-induced tinnitus can be caused by peripheral and central effects.

A possible explanation for the suppressive effects of GJG on salicylate-induced tinnitus includes mechanisms via the transient receptor potential vanilloid 1 (TRPV1) channel [55]. TRPV1 channels are expressed in cochlear spiral ganglion cells, and the expression levels are upregulated by salicylate [16]. When TRPV1 channels are antagonized by a specific TRPV1 antagonist (capsazepine), salicylate-induced tinnitus behavior is suppressed [16]. A suppressive effect of GJG through TRP channels in oxaliplatin-induced acute neuropathy has also been reported [22]. Therefore, GJG might suppress FP scores and reduce the number of c-Fos-expressing cells through the modulation of TRPV1 channels. However, suppressive effects of GJG on TRPV1 in the cochlea have not been confirmed yet. Another possible explanation for the suppressive effects of GJG on salicylate-induced tinnitus includes the effects of increased peripheral blood flow. Dider et al. [34] reported that salicylate reduced cochlear blood flow. Kono et al. [56] reported that GJG ameliorated the oxaliplatin-induced decrease in peripheral blood flow. Therefore, GJG might suppress FP scores and reduce the number of c-Fos-expressing cells through increasing cochlear blood flow. However, increasing effects of GJG on blood flow in the cochlea have not been confirmed yet. On the other hand, GJG may directly act on central neurons. Several neuroprotective compounds of GJG (loganin, morroniside, catalpol, and paeoniflorin) were detected at high levels in the plasma of jugular vein blood shortly after oral GJG administration to rats [56]. This raises the possibility of a direct action of GJG on central
neurons. In support of this notion, evidence suggesting direct GJG actions on central neurons is accumulating [56,57].

The limitations of this study are as follows. The rats used in our study were not old, because older rats have reduced memory and physical strength. It should be noted that this is not the same age at which tinnitus commonly occurs in humans. Although we examined only males in this study, the sex difference may affect behavioral tests or the auditory system [58]. However, there are reports that it can be used regardless of gender, even if the estrous cycle is present [59]. In any case, the effect of animal sex on the tinnitus behavioral model has not been examined. We performed immunohistochemical experiments and confirmed the suppression of c-Fos expression, but we did not evaluate the tinnitus behavior of these individuals as in the previous literature [16,21].

The question is whether our defined tinnitus behavior in rats really represent the presence of tinnitus. There is an experimental system that evaluated our FP (moved in the absence of stimuli) as a stress response. Depner et al. [60] reported an amplitude modulation study in which conditioning was performed by applying electrical stimuli in a shuttle box. Although not exactly the same conditioning, the behavior between sound stimuli was defined as inter-trial crossings (ITC), which are a measure of activity mainly describing the stress in animals. It is important to note that Depner’s study was not an experiment that examined tinnitus. Kizawa’s method [16] had already been reported as an established method for evaluating tinnitus behavior; thus, we believed that it would be possible to evaluate tinnitus by using this method. However, we cannot rule out the possibility that the FP scores we evaluated are affected by other factors such as stress in addition to active avoidance due to tinnitus.

In tinnitus evaluation, the gap detection test [6] has recently been adopted in a number of tinnitus behavioral experiments [38,61]. Since no conditioning was involved, unnecessary stress caused by conditioning may be less than that in our experiment. We evaluated tinnitus behavior using a method that can be validated at our facility, and we believe that Kizawa et al. ’s method is sufficient to evaluate tinnitus.

5. Conclusions

We modeled tinnitus and demonstrated that GJG suppressed tinnitus behavior. We also demonstrated that GJG suppressed the increase in c-Fos expression by salicylate. Our study provided the first evidence that GJG suppressed tinnitus, which had never been presented in animal studies. The results provide evidence for future clinical trials of GJG. We hope that this study will help establish a clinical treatment for tinnitus.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/brainsci12050587/s1, Figure S1: Learning curves before behavioral tests.

Author Contributions: Conceptualization, K.K., A.Y., T.S., T.O., M.S., D.O., T.K., and Y.S.; methodology, K.K., A.Y., T.S., T.O., T.K. and Y.S.; software, K.K., T.S.; validation, K.K., A.Y., T.S., T.O., M.S., D.O.; formal analysis, K.K.; investigation, K.K. and T.S.; resources, K.K., A.Y., T.S., T.K. and Y.S.; data curation, K.K. and T.S.; writing—original draft preparation, K.K., T.K. and Y.S.; writing—review and editing, K.K., A.Y., T.S., T.O. and Y.S.; visualization, K.K.; supervision, T.K. and Y.S.; project administration, T.K. and Y.S.; funding acquisition, K.K., A.Y., and T.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by JSPS KAKENHI Grant (2020–2022), AMED under Grant Number 18dk0310092h000a, Health and Labour Sciences Research Grant for Research on Rare and Intractable Diseases (R03-Nancho-Ippan) from the Ministry of Health, Labour and Welfare of Japan, and Tsumura & Co. Ltd.

Institutional Review Board Statement: The study was conducted in accordance with the guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board of Nara Medical University (protocol code: 12310 and approval date: 8 June 2018).

Informed Consent Statement: Not applicable.
Data Availability Statement: The data that support the findings of this study are available from the first author, K.K., upon reasonable request.

Acknowledgments: The authors thank Masashi Choubi, a registered statistician (certificate number: 622017) for helpful advice on statistical analyses, Yoshihiko Sagatani for helpful advice on setting up the experimental environment, and Takashi Inoue for helpful advice on statistical analyses.

Conflicts of Interest: Tsumura & Co. Ltd., Japan provided funding, the drug (GJG), reference papers, and advice on the design of the study, but had no role in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. McCormack, A.; Edmondson-Jones, M.; Somerset, S.; Hall, D. A systematic review of the reporting of tinnitus prevalence and severity. *Hear. Res.* 2016, 337, 70–79. [CrossRef] [PubMed]

2. Fujii, K.; Nagata, C.; Nakamura, K.; Kawachi, T.; Takatsuka, N.; Oba, S.; Shimizu, H. Prevalence of tinnitus in community-dwelling Japanese adults. *J. Epidemiol.* 2011, 21, 299–304. [CrossRef] [PubMed]

3. Eggermont, J.J.; Roberts, L.E. The neuroscience of tinnitus. *Trends Neurosci.* 2004, 27, 676–682. [CrossRef] [PubMed]

4. Eggermont, J.J. Hearing loss, hyperacusis, or tinnitus: What is modeled in animal research? *Hear. Res.* 2013, 295, 140–149. [CrossRef]

5. Eggermont, J.J. The auditory cortex and tinnitus—A review of animal and human studies. *Eur. J. Neurosci.* 2015, 41, 665–676. [CrossRef] [PubMed]

6. Turner, J.G. Behavioral measures of tinnitus in laboratory animals. *Prog. Brain Res.* 2007, 166, 147–156. [CrossRef]

7. Jastreboff, P.J.; Brennan, J.F.; Coleman, J.K.; Sasaki, C.T. Phantom auditory sensation in rats: An animal model for tinnitus. *Behav. Neurosci.* 1988, 102, 811–822. [CrossRef]

8. Jastreboff, P.J.; Brennan, J.F.; Sasaki, C.T. An animal model for tinnitus. *Laryngoscope* 1988, 98, 280–286. [CrossRef]

9. Bauer, C.A.; Brozoski, T.J.; Rojas, R.; Boley, J.; Wyder, M. Behavioral model of chronic tinnitus in rats. *Otolaryngol. Head Neck Surg.* 1999, 121, 457–462. [CrossRef]

10. Bauer, C.A.; Brozoski, T.J. Assessing tinnitus and prospective tinnitus therapeutics using a psychophysical animal model. *J. Assoc. Res. Otolaryngol.* 2001, 2, 54–64. [CrossRef] [PubMed]

11. Guitton, M.J.; Caston, J.; Ruol, J.; Johnson, R.M.; Pujol, R.; Puel, J.L. Salicylate induces tinnitus through activation of cochlear NMDA receptors. *J. Neurosci.* 2003, 23, 3944–3952. [CrossRef] [PubMed]

12. Uno, T.; Ohsawa, I.; Tokudome, M.; Sato, Y. Effects of Goshajinkigan on insulin resistance in patients with type 2 diabetes. *Diabetes Res. Clin. Pract.* 2005, 69, 129–135. [CrossRef] [PubMed]

13. Tawata, M.; Kuribara, A.; Nitta, K.; Iwase, E.; Gan, N.; Onaya, T. The effects of goshajinkigan, a herbal medicine, on subjective symptoms and vibratory threshold in patients with diabetic neuropathy. *Diabetes Res. Clin. Pract.* 1994, 26, 121–128. [CrossRef]

14. Usuki, Y.; Usuki, S.; Hommura, S. Successful treatment of a senile diabetic woman with cataract with goshajinkigan. *Am. J. Chin. Med.* 1991, 19, 259–263. [CrossRef]

15. Ohnishi, S.; Sawai, S.; Tsuiyahi, K.; Hiraig, K.; Taniuchi, A.; Furukawa, M.; Wada, H.; Tanaka, Y.; Ito, M.; Bono, K.; et al. Effect of TJ-107 (Tsumura Goshajinkigan) on tinnitus in a multicenter clinical trial. *Jibinkoukatenbo* 1994, 37, 371–379. (In Japanese)

16. Kizawa, K.; Kitahara, T.; Hori, A.; Maekawa, C.; Kuramatsu, T.; Kawashima, T.; Nishikawa, S.; Doi, K.; Inoue, H. Behavioral assessment and identification of a molecular marker in a salicylate-induced tinnitus in rats. *Neuroscience* 2010, 165, 1323–1332. [PubMed]

17. Wallhäusser-Franke, E. Salicylate evokes c-fos expression in the brain stem: Implications for tinnitus. *Neuroreport* 1997, 8, 725–728. [CrossRef]

18. Wallhäusser-Franke, E.; Mahlke, C.; Oliva, R.; Braun, S.; Wenz, G.; Langner, G. Expression of c-fos in auditory and non-auditory brain regions of the gerbil after manipulations that induce tinnitus. *Exp. Brain Res.* 2003, 153, 649–654. [CrossRef]

19. Wu, J.L.; Chiu, T.W.; Poon, P.W. Differential changes in Fos-immunoreactivity at the auditory brainstem after chronic injections of salicylate in rats. *Hear. Res.* 2003, 176, 80–93. [CrossRef]

20. Mahlke, C.; Wallhäusser-Franke, E. Evidence for tinnitus-related plasticity in the auditory and limbic system, demonstrated by arg3.1 and c-fos immunocytochemistry. *Hear. Res.* 2004, 185, 17–34. [CrossRef]

21. Santos, P.; da Silva, L.E.; Leão, R.M. Specific immediate early gene expression induced by high doses of salicylate in the cochlear nucleus and inferior colliculus of the rat. *Braz. J. Otorhinolaryngol.* 2017, 83, 155–161. [CrossRef] [PubMed]

22. Mizuno, K.; Kono, T.; Suzuki, Y.; Miyagi, C.; Omiya, Y.; Miyano, K.; Kase, Y.; Uezono, Y. Goshajinkigan, a traditional Japanese medicine, prevents oxaliplatin-induced acute peripheral neuropathy by suppressing functional alteration of TRP channels in rat. *J. Pharm. Sci.* 2014, 103, 91–98. [CrossRef] [PubMed]

23. Suzuki, Y.; Goto, K.; Ishige, A.; Komatsu, Y.; Kamei, J. Antinociceptive effect of Goshajinkigan, a Kampo medicine, in streptozotocin-induced diabetic mice. *Ipn J. Pharmacol.* 1999, 79, 169–175. [CrossRef] [PubMed]

24. Ushio, S.; Egashira, N.; Sada, H.; Kawashiri, T.; Shirahama, M.; Masuguchi, K.; Oishi, R. Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents. *Eur. J. Cancer* 2012, 48, 1407–1413. [CrossRef] [PubMed]
Brain Sci. 2022, 12, 587

25. Paxinos, G.; Watson, C. The Rat Brain in Stereotaxic Coordinates, 6th ed.; Academic Press: Burlington, VT, USA, 2007.

26. Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; Preibisch, S.; Rueden, C.; Saalfeld, S.; Schmid, B.; et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 2012, 9, 676–682. [CrossRef] [PubMed]

27. Jastreboff, P.J.; Brennan, J.F. Evaluating the loudness of phantom auditory perception (tinnitus) in rats. Audiology 1994, 33, 202–217. [CrossRef]

28. Turner, J.G.; Brozoski, T.J.; Bauer, C.A.; Parrish, J.L.; Myers, K.; Hughes, L.F.; Caspary, D.M. Gap detection deficits in rats with tinnitus: A potential novel screening tool. Behav. Neurosci. 2006, 120, 188–195. [CrossRef]

29. Zheng, Y.; Seung Lee, H.; Smith, P.F.; Darlington, C.L. Neuronal nitric oxide synthase expression in the cochlear nucleus in a salicylate model of tinnitus. Brain Res. 2006, 1123, 201–206. [CrossRef]

30. Basta, D.; Ernst, A. Effects of salicylate on spontaneous activity in inferior colliculus brain slices. Hear. Res. 2007, 226, 244–253. [CrossRef]

31. Peng, B.G.; Chen, S.; Lin, X. Aspirin selectively augmented N-methyl-D-aspartate types of glutamate responses in cultured spiral ganglion neurons of mice. Neurosci. 2009, 159, 325–334. [CrossRef]

32. Boettcher, F.A.; Bancroft, B.R.; Salvi, R.J. Concentration of salicylate in serum and perilymph of the chinchilla. Hear. Res. 2008, 244, 232–245. [CrossRef] [PubMed]

33. Zhang, X.; Yang, P.; Cao, Y.; Qin, L.; Sato, Y. Salicylate induced neural changes in the primary auditory cortex of awake cats. Eur. J. Histochem. 2014, 58, 2294. [CrossRef] [PubMed]

34. Lanaia, V.; Tziridis, K.; Schulze, H. Salicylate-Induced Changes in Hearing Thresholds in Mongolian Gerbils Are Correlated with Tinnitus Frequency but Not with Tinnitus Strength. Neuroscience 2006, 28, 4881–4889. [CrossRef]

35. Egggermont, J.J.; Kenmochi, M. Salicylate and quinine selectively increase spontaneous firing rates in secondary auditory cortex. Hear. Res. 1998, 117, 149–160. [CrossRef]

36. Sun, W.; Lu, J.; Stolzberg, D.; Gray, L.; Deng, A.; Lobarinias, E.; Salvi, R.J. Salicylate increases the gain of the central auditory system. Neuroscience 2009, 159, 325–334. [CrossRef]

37. Rezapour, M.; Moossavi, A. Tinnitus induction in animals and its impact on auditory system structure. Hear. Res. 2010, 31, 823–831. [CrossRef]

38. Egermont, J.J.; Kenmochi, M. Salicylate and quinine selectively increase spontaneous firing rates in secondary auditory cortex. Hear. Res. 1998, 117, 149–160. [CrossRef]

39. Sun, W.; Lu, J.; Stolzberg, D.; Gray, L.; Deng, A.; Lobarinias, E.; Salvi, R.J. Salicylate increases the gain of the central auditory system. Neuroscience 2009, 159, 325–334. [CrossRef]

40. Jastreboff, P.J.; Hansen, R.; Sasaki, P.G.; Sasaki, C.T. Differential uptake of salicylate in serum, cerebrospinal fluid, and perilymph. J. Neurosci. 2008, 28, 7313–7323. [CrossRef] [PubMed]

41. cherry, T.C.; Li, X.; Liu, L.; Wang, J.; Lu, C.Q.; Yang, M.; Jiao, Y.; Zang, F.C.; Radziwon, K.; Chen, G.D.; et al. Tinnitus and hyperacusis involve hyperactivity and enhanced connectivity in auditory-limbic-auriculo-cerebellar network. Elife 2015, 4, e06576. [CrossRef]

42. Salvi, R.; Radziwon, K.; Manohar, S.; Auerbach, B.; Ding, D.; Liu, C.; Chen, Y.C.; Chen, G.D.; et al. Review: Neural Mechanisms of Tinnitus and Hyperacusis in Acute Drug-Induced Ototoxicity. Am. J. Audiol. 2021, 30, 901–915. [CrossRef]

43. Kakehata, S.; Santos-Sacchi, J. Effects of salicylate and lanthanides on outer hair cell motility and associated gating charge. J. Neurosci. 1996, 16, 4881–4889. [CrossRef]

44. Peng, B.G.; Cherry, T.C.; Li, X. Aspirin selectively augmented N-methyl-D-aspartate types of glutamate responses in cultured spiral ganglion neurons of mice. Neurosci. Lett. 2003, 343, 21–24. [CrossRef]

45. Ruel, J.; Chabbert, C.; Nouvian, R.; Bendris, R.; Eybalin, M.; Leger, C.L.; Bourien, J.; Mersel, M.; Puel, J.L. Salicylate enables cochlear arachidonic-acid-sensitive NMDA receptor responses. J. Neurosci. 2008, 28, 7313–7323. [CrossRef] [PubMed]

46. Deer, B.C.; Hunter-Duvar, I. Salicylate toxicity model of tinnitus in the chinchilla: A behavioral and electron microscope study. J. Otalaryngol. 1982, 11, 260–264. [PubMed]

47. Jastreboff, P.J.; Hansen, R.; Sasaki, P.G.; Sasaki, C.T. Differential uptake of salicylate in serum, cerebrospinal fluid, and perilymph. Arch. Otalaryngol. Head Neck Surg. 1986, 112, 1050–1053. [CrossRef]

48. Boettcher, F.A.; Bancroft, B.R.; Salvi, R.J. Concentration of salicylate in serum and perilymph of the chinchilla. Arch. Otalaryngol. Head Neck Surg. 1990, 116, 681–684. [PubMed]

49. Rezapour, M.; Moossavi, A. Tinnitus induction in animals and its impact on auditory system structure. Aud. Vestib. Res. 2019, 28, 204–216. [CrossRef]

50. Stolzberg, D.; Salvi, R.J.; Allman, B.L. Salicylate toxicity model of tinnitus. Front. Syst. Neurosci. 2012, 6, 28. [CrossRef]

51. Basta, D.; Ernst, A. Effects of salicylate on spontaneous activity in inferior colliculus brain slices. Neurosci. Res. 2004, 50, 237–243. [CrossRef]

52. Basta, D.; Goetzke, R.; Ernst, A. Effects of salicylate application on the spontaneous activity in brain slices of the mouse cochlear nucleus, medial geniculate body and primary auditory cortex. Hear. Res. 2008, 240, 42–51. [CrossRef]

53. Lu, Y.G.; Tang, Z.Q.; Ye, Z.Y.; Wang, H.T.; Huang, Y.N.; Zhou, K.Q.; Zhang, M.; Xu, T.L.; Chen, L. Salicylate, an aspirin metabolite, specifically inhibits the current mediated by glycine receptors containing alpha1-subunits. Br. J. Pharmacol. 2009, 157, 1514–1522. [CrossRef]

54. Su, Y.Y.; Luo, B.; Wang, H.T.; Chen, L. Differential effects of sodium salicylate on current-evoked firing of pyramidal neurons and fast-spiking interneurons in slices of rat auditory cortex. Hear. Res. 2009, 253, 60–66. [CrossRef] [PubMed]

55. Wang, H.T.; Luo, B.; Zhou, K.Q.; Xu, T.L.; Chen, L. Sodium salicylate reduces inhibitory postsynaptic currents in neurons of rat auditory cortex. Hear. Res. 2006, 215, 77–83. [CrossRef] [PubMed]
54. Domarecka, E.; Olze, H.; Szczepak, A.J. Auditory Brainstem Responses (ABR) of Rats during Experimentally Induced Tinnitus: Literature Review. *Brain Sci.* 2020, 10, 901. [CrossRef] [PubMed]

55. Caterina, M.J.; Schumacher, M.A.; Tominaga, M.; Rosen, T.A.; Levine, J.D.; Julius, D. The capsaicin receptor: A heat-activated ion channel in the pain pathway. *Nature* 1997, 389, 816–824. [CrossRef]

56. Kono, T.; Suzuki, Y.; Mizuno, K.; Miyagi, C.; Omiya, Y.; Sekine, H.; Mizuhara, Y.; Miyano, K.; Kase, Y.; Uezono, Y. Preventive effect of oral goshajinkigan on chronic oxaliplatin-induced hypoesthesia in rats. *Sci. Rep.* 2015, 5, 16078. [CrossRef]

57. Jiang, S.; Baba, K.; Okuno, T.; Kinoshiha, M.; Choong, C.J.; Hayakawa, H.; Sakiyama, H.; Ikenaka, M.; Nagano, S.; Sasaki, T.; et al. Go-sha-jinki-Gan Alleviates Inflammation in Neurological Disorders via p38-TNF Signaling in the Central Nervous System. *Neurotherapeutics* 2021, 18, 460–473. [CrossRef]

58. Krizman, J.; Rotondo, E.K.; Nicol, T.; Kraus, N.; Biesczad, K.M. Sex differences in auditory processing vary across estrous cycle. *Sci. Rep.* 2021, 11, 22898. [CrossRef]

59. Becker, J.B.; Prendergast, B.J.; Liang, J.W. Female rats are not more variable than male rats: A meta-analysis of neuroscience studies. *Biol. Sex Differ.* 2016, 7, 34. [CrossRef]

60. Depner, M.; Tziridis, K.; Hess, A.; Schulze, H. Sensory cortex lesion triggers compensatory neuronal plasticity. *BMC Neurosci.* 2014, 15, 57. [CrossRef]

61. Tziridis, K.; Ahlf, S.; Jeschke, M.; Happel, M.F.; Ohl, F.W.; Schulze, H. Noise Trauma Induced Neural Plasticity Throughout the Auditory System of Mongolian Gerbils: Differences between Tinnitus Developing and Non-Developing Animals. *Front. Neurol.* 2015, 6, 22. [CrossRef]